Compare CLMB & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | ASMB |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 512.1M |
| IPO Year | 1996 | 2010 |
| Metric | CLMB | ASMB |
|---|---|---|
| Price | $32.62 | $20.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $32.33 | ★ $52.00 |
| AVG Volume (30 Days) | 127.1K | ★ 204.2K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | 14.29 | ★ 91.78 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $652,517,000.00 | N/A |
| Revenue This Year | $12.32 | N/A |
| Revenue Next Year | $9.32 | N/A |
| P/E Ratio | $67.89 | ★ N/A |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $15.25 | $19.30 |
| 52 Week High | $79.12 | $39.71 |
| Indicator | CLMB | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 36.54 |
| Support Level | $30.82 | N/A |
| Resistance Level | $34.14 | $21.93 |
| Average True Range (ATR) | 1.08 | 1.05 |
| MACD | -0.17 | 0.20 |
| Stochastic Oscillator | 56.71 | 26.27 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.